Abstract
Neutrophils are increasingly being investigated for their potential to be used as an immunotherapy for cancer. Research into this area has demonstrated that neutrophils can target and destroy cancer cells and stimulate an immune response to fight the cancer. The next step in this research is to understand how to optimize the use of neutrophils for cancer immunotherapy and to identify potential therapeutic targets. One concern is the possibility of excessive inflammation caused by the activated neutrophils, which could lead to tissue damage and adverse immune reactions in patients. Additionally, there may be a risk of off-target effects where neutrophils attack healthy cells instead of cancerous ones. Investigating these potential side effects and developing strategies to minimize them will be essential for ensuring the safety and efficacy of neutrophil-based therapies in clinical settings.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
